finanzen.net
23.08.2019 18:30
Bewerten
(0)

Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer

Alexion Pharmaceuticals (ALXN) is likely "on the radar" as a takeover candidate, but biotech company Amgen (AMGN) doesn't fit logically as an acquirer, says one analyst.XSpanish news site Intereconomia.com reported Thursday that Amgen could be nearing a deal to buy Alexion for $200 a share. Although the price tag makes sense, Amgen as a buyer doesn't, SVB Leerink analyst Geoffrey Porges said in a report to clients.The top biotech company seems to be fully committed to oncology, neurology and immunology, Porges said. Alexion, on the other hand, specializes in rare diseases. Alexion is a rare asset with no competitive, regulatory, operational or manufacturing challenges in sight, he said.In the last 18 months, such considerations drove large biotech takeovers. Porges noted Takeda Pharmaceutical's (TAK) acquisition of Shire, as well as pending buyouts of Celgene (CELG) and Allergan (AGN) by Bristol-Myers Squibb (BMY) and AbbVie (ABBV), respectively. The same could be true for Alexion, he said."We see Alexion as a prime candidate for generating positive results based on these considerations, and in our view its recent price should be 'on the radar screen' for many large acquirers," he said.Could Alexion Stock Be Taken Over?On the stock market today, Alexion stock tumbled 6.6%, to 115.33. Amgen stock also fell 2.1%, to 199.08. On Thursday, following the report, Alexion stock popped 7.5% as Amgen stock lost a fraction.Alexion "is a highly attractive, fungible, accretive asset that is likely to be materially more valuable in the hands of a diversified company than it is alone," Porges said.The biotech company makes Soliris, a treatment for several rare diseases of the blood, muscles, optic nerve and spinal cord. In addition to several other drugs, Alexion also gained approval for a next-generation form of Soliris, dubbed Ultomiris, in a blood disease.There are no competitive, regulatory, operational or manufacturing surprises pending that could disrupt Alexion, Porges said. Diversified biotech companies like that tend to have durable sales and cash flow. As a result, he expects Alexion stock could command a premium."We believe there is a desperate scarcity of such assets across the industry, and for this reason, investors should anticipate a hefty premium, if a genuine acquirer materializes," he said. "However, we don't think that Amgen is the most logical such acquirer."Biotech Company Amgen Has A Different FocusAmgen's biggest product is blockbuster drug Enbrel, which treats forms of arthritis and psoriasis."Amgen has eschewed rare disease businesses and products, and seems to have fully committed themselves to their strategic business areas of oncology, neurology and immunology," he said. "Of course Amgen could change course, and Alexion is an extremely rare asset in the industry today."The biggest biotech company is actually planning to swipe some of Alexion's sales with a biosimilar version of Soliris. Amgen is currently in a Phase 3 study of its copycat drug. That's partly why Alexion created Ultomiris — to help lessen the impact of biosimilars when Soliris's patents expire.If interested, Amgen would have to cough up at least 150-200 per share of Alexion stock, he said. Porges noted the average premium over 30-day average share price in the deals for Shire, Celgene and Allergan was 54%. That could put the offer for Alexion stock in the range of 165-190 a share."Most likely, given recent premiums and the scarcity of Alexion's size, profitability and growth profile, a price of about 200 per share (or higher) would be required in our view to close the deal," he said.Porges kept his outperform rating on Alexion stock.Follow Allison Gatlin on Twitter at @IBD_AGatlin.YOU MIGHT ALSO LIKE:Should You Buy Pharma Giant Merck? Here's What Earnings, Merck Stock Chart SayWhy Analysts Are Upbeat On Sarepta Despite A Notable FDA RejectionRun Custom Stock Screens With MarketSmithWatch IBD's Investing Strategies Show For Actionable Market InsightsLooking For The Next Big Stock Market Winners? Start With These 3 StepsThe post Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer appeared first on Investor's Business Daily.
Weiter zum vollständigen Artikel bei "Investors Business Daily"
Quelle: Investors Business Daily

Nachrichten zu Amgen Inc.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Amgen Inc.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
21.05.2019Amgen Sector PerformRBC Capital Markets
15.03.2019Amgen OutperformBMO Capital Markets
01.02.2019Amgen Sector PerformRBC Capital Markets
30.01.2019Amgen NeutralJP Morgan Chase & Co.
17.01.2019Amgen Sector PerformRBC Capital Markets
15.03.2019Amgen OutperformBMO Capital Markets
17.01.2019Amgen buyGoldman Sachs Group Inc.
08.12.2018Amgen buyGoldman Sachs Group Inc.
04.12.2018Amgen buyGoldman Sachs Group Inc.
04.12.2018Amgen overweightMorgan Stanley
21.05.2019Amgen Sector PerformRBC Capital Markets
01.02.2019Amgen Sector PerformRBC Capital Markets
30.01.2019Amgen NeutralJP Morgan Chase & Co.
17.01.2019Amgen Sector PerformRBC Capital Markets
14.01.2019Amgen Sector PerformRBC Capital Markets
15.11.2012Amgen verkaufenHamburger Sparkasse AG (Haspa)
31.07.2012Amgen verkaufenHamburger Sparkasse AG (Haspa)
01.02.2012Amgen verkaufenHamburger Sparkasse AG (Haspa)
20.12.2011Amgen verkaufenHamburger Sparkasse AG (Haspa)
30.07.2008Amgen UpgradeIndependent Research GmbH

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amgen Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht fester aus der Woche -- US-Börsen schließen lustlos -- Kone schlägt thyssenkrupp-Beteiligung bei Aufzugfusion vor -- Goldman Sachs kappt Apple-Kursziel -- VW, Deutsche Bank im Fokus

TLG Immobilien will weitere Anteile an Aroundtown. Google, Amazon & Co. betroffen: US-Abgeordnete fordern interne Unterlagen von Tech-Konzernen ein. Bundesregierung ist gegen Einführung von Facebooks Kryptocoin Libra. Londoner Börse lehnt 35-Milliarden-Euro-Offerte aus Hongkong ab. RIB Software hebt Prognose für 2019 an.

Umfrage

Sind Sie in Gold investiert?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Microsoft Corp.870747
Daimler AG710000
Scout24 AGA12DM8
Apple Inc.865985
Amazon906866
Wirecard AG747206
Allianz840400
TeslaA1CX3T
BASFBASF11
E.ON SEENAG99
Ballard Power Inc.A0RENB
BMW AG519000
Infineon AG623100
CommerzbankCBK100